| Ident. | Authors (with country if any) | Title |
|---|
| 004102 (2014) |
S. P. Choukem [France, Cameroun] ; C. Fabreguettes [France] ; E. Akwo [Cameroun] ; R. Porcher [France] ; J. L. Nguewa [France] ; C. Bouche [France] ; F. F. Kaze [Cameroun] ; A. P. Kengne [Afrique du Sud, Australie] ; P. Vexiau [France] ; J. C. Mbanya [Cameroun] ; E. Sobngwi [Cameroun] ; J.-F. Gautier [France] | Influence of migration on characteristics of type 2 diabetes in sub-Saharan Africans |
| 004115 (2014) |
Sophia Zoungas [Australie] ; Mark Woodward [Australie, États-Unis] ; QIANG LI [Australie] ; Mark E. Cooper [Australie] ; Pavel Hamet [Canada] ; Stephen Harrap [Australie] ; Simon Heller [Royaume-Uni] ; Michel Marre [France] ; Anushka Patel [Australie] ; Neil Poulter [Royaume-Uni] ; Bryan Williams [Royaume-Uni] ; John Chalmers [Australie] | Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes |
| 004155 (2014) |
S. Zoungas [Australie] ; J. Chalmers [Australie] ; B. Neal [Australie] ; L. Billot [Australie] ; Q. Li [Australie] ; Y. Hirakawa [Australie] ; H. Arima [Australie] ; H. Monaghan [Australie] ; R. Joshi [Australie] ; S. Colagiuri [Australie] ; M. E. Cooper [Australie] ; P. Glasziou [Australie] ; D. Grobbee [Pays-Bas] ; P. Hamet [Canada] ; S. Harrap [Australie] ; S. Heller [Royaume-Uni] ; L. Lisheng [République populaire de Chine] ; G. Mancia [Italie] ; M. Marre [France] ; D. R. Matthews [Royaume-Uni] ; C. E. Mogensen [Danemark] ; V. Perkovic [Australie] ; N. Poulter [Royaume-Uni] ; A. Rodgers [Australie] ; B. Williams [Royaume-Uni] ; S. Macmahon [Australie, Royaume-Uni] ; A. Patel [Australie] ; M. Woodward [Australie, Royaume-Uni, États-Unis] | Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes |
| 004199 (2014) |
Paul Welsh [Royaume-Uni] ; Mark Woodward [Australie] ; Graham S. Hillis [Australie] ; QIANG LI [Australie] ; Michel Marre [France] ; Bryan Williams [Royaume-Uni] ; Neil Poulter [Royaume-Uni] ; Louise Ryan [Australie] ; Stephen Harrap [Australie] ; Ansuhka Patel [Australie] ; John Chalmers [Australie] ; Naveed Sattar [Royaume-Uni] | Do Cardiac Biomarkers NT-proBNP and hsTnT Predict Microvascular Events in Patients With Type 2 Diabetes? Results From the ADVANCE Trial |
| 004255 (2014) |
Gordon Lowe [Royaume-Uni] ; Mark Woodward [Australie] ; Graham Hillis [Australie] ; Ann Rumley [Royaume-Uni] ; QIANG LI [Australie] ; Stephen Harrap [Australie] ; Michel Marre [France] ; Pavel Hamet [Canada] ; Anushka Patel [Australie] ; Neil Poulter [Royaume-Uni] ; John Chalmers [Australie] | Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study |
| 004C24 (2013) |
Jamie Morton [Australie] ; Martin K. C. Ng [Australie] ; John Chalmers [Australie] ; Mark Woodward [Australie] ; Giuseppe Mancia [Italie] ; Neil R. Poulter [Royaume-Uni] ; Michel Marre [France] ; Mark E. Cooper [Australie] ; Sophia Zoungas [Australie] | The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality? |
| 005937 (2012) |
Michaela Diamant [Pays-Bas] ; Luc Van Gaal [Belgique] ; Stephen Stranks [Australie] ; Bruno Guerci [France] ; Leigh Macconell [États-Unis] ; Harry Haber [États-Unis] ; Jamie Scism-Bacon [États-Unis] ; Michael Trautmann [États-Unis] | Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks |
| 005990 (2012) |
Meg J. Jardine [Australie] ; Jun Hata [Australie] ; Mark Woodward [Australie] ; Vlado Perkovic [Australie] ; Toshiharu Ninomiya [Australie] ; Hisatomi Arima [Australie] ; Sophia Zoungas [Australie] ; Alan Cass [Australie] ; Anushka Patel [Australie] ; Michel Marre [France] ; Giuseppe Mancia [Italie] ; Carl E. Mogensen [Danemark] ; Neil Poulter [Royaume-Uni] ; John Chalmers [Australie] | Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes |
| 005B61 (2012) |
Liana K. Billings [États-Unis] ; Yi-Hsiang Hsu [États-Unis] ; Rachel J. Ackerman [États-Unis] ; Josee Dupuis [États-Unis] ; Benjamin F. Voight [États-Unis] ; Laura J. Rasmussen-Torvik [États-Unis] ; Serge Hercberg [France] ; Mark Lathrop [France] ; Daniel Barnes [Royaume-Uni] ; Claudia Langenberg [Royaume-Uni] ; JENNIE HUI [Australie] ; MAO FU [États-Unis] ; Nabila Bouatia-Naji [France] ; Cecile Lecoeur [France] ; PING AN [États-Unis] ; Patrik K. Magnusson [Suède] ; Ida Surakka [États-Unis] ; Samuli Ripatti [États-Unis] ; Lene Christiansen [Danemark] ; Christine Dalgard [Danemark] ; Lasse Folkersen [Suède] ; Elin Grundberg [Royaume-Uni] ; Per Eriksson [Suède] ; Jaakko Kaprio [États-Unis] ; KIRSTEN OHM KYVIK ; Nancy L. Pedersen [Suède] ; Ingrid B. Borecki [États-Unis] ; Michael A. Province [Suède] ; Beverley Balkau ; Philippe Froguel [France] ; Alan R. Shuldiner [États-Unis] ; Lyle J. Palmer ; Nick Wareham [Royaume-Uni] ; Pierre Meneton ; Toby Johnson ; James S. Pankow ; David Karasik [États-Unis] ; James B. Meigs [États-Unis] ; Douglas P. Kiel [États-Unis] ; Jose C. Florez [États-Unis] | Impact of Common Variation in Bone-Related Genes on Type 2 Diabetes and Related Traits |
| 006388 (2011) |
L. Chen [Australie] ; D. J. Magliano [Australie] ; B. Balkau [Australie, France] ; R. Wolfe [Australie] ; L. Brown [Australie] ; A. M. Tonkin [Australie] ; P. Z. Zimmet [Australie] ; J. E. Shaw [Australie] | Maximizing efficiency and cost‐effectiveness of Type 2 diabetes screening: the AusDiab study |
| 006541 (2011) |
Charlotte L. Mattsson [Suède] ; Robert I. Csikasz [Suède] ; Ekaterina Chernogubova [Suède] ; Daniel L. Yamamoto [Suède] ; Helena T. Hogberg [Suède] ; Ez-Zoubir Amri [France] ; Dana S. Hutchinson [Suède, Australie] ; Tore Bengtsson [Suède] | β1-Adrenergic receptors increase UCP1 in human MADS brown adipocytes and rescue cold-acclimated β3-adrenergic receptor-knockout mice via nonshivering thermogenesis |
| 006823 (2011) |
Paul J. W. H. Kappelle [Pays-Bas] ; Gilles Lambert [Australie, France] ; Robin P. F. Dullaart [Pays-Bas] | Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24 h insulin infusion in healthy subjects and type 2 diabetic patients |
| 006987 (2011) |
Bernard Zinman [Canada] ; Greg Fulcher [Australie] ; Paturi V. Rao [Inde] ; Nihal Thomas [Inde] ; Lars A. Endahl [Danemark] ; Thue Johansen [États-Unis] ; Rebecka Lindh [États-Unis] ; Andrew Lewin [États-Unis] ; Julio Rosenstock [États-Unis] ; Michel Pinget [France] ; Chantal Mathieu [Belgique] | Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial |
| 006B22 (2011) |
P. L. Drury [Nouvelle-Zélande] ; R. Ting [Australie] ; D. Zannino [Australie] ; C. Ehnholm [Finlande] ; J. Flack [Australie] ; M. Whiting [Australie] ; R. Fassett [Australie] ; J.-C. Ansquer [France] ; P. Dixon [Nouvelle-Zélande] ; T. M. E. Davis [Australie] ; C. Pardy [Australie] ; P. Colman [Australie] ; A. Keech [Australie] | Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study |
| 007372 (2010) |
André-Pascal Kengne [Australie] ; Sébastien Czernichow [Australie, France] ; John Chalmers [Australie] | Variables tensionnelles et risque cardiovasculaire chez les diabétiques de type 2 dans l'étude ADVANCE |
| 007662 (2010) |
Q. Li [Australie] ; J. Chalmers [Australie] ; S. Czernichow [Australie, France] ; B. Neal [Australie] ; B. A. Taylor [Norvège] ; S. Zoungas [Australie] ; N. Poulter [Royaume-Uni] ; M. Woodward [Australie, États-Unis] ; A. Patel [Australie] ; B. De Galan [Australie, Pays-Bas] ; G. D. Batty [Australie, Royaume-Uni] | Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial |
| 007877 (2010) |
G. David Batty [Royaume-Uni, Australie] ; QIANG LI [Australie] ; Sébastien Czernichow [Australie, France] ; Bruce Neal [Australie] ; Sophia Zoungas [Australie] ; Rachel Huxley [Australie] ; Anushka Patel [Australie] ; Bastiaan E. De Galan [Australie, Pays-Bas] ; Mark Woodward [Australie, États-Unis] ; Pavel Hamet [Canada] ; Stephen B. Harrap [Australie] ; Neil Poulter [Royaume-Uni] ; John Chalmers [Australie] | Erectile Dysfunction and Later Cardiovascular Disease in Men With Type 2 Diabetes: Prospective Cohort Study Based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) Trial |
| 007917 (2010) |
Liffert Vogt [Pays-Bas, Italie] ; Carlos Chiurchiu [Italie] ; Harbajan Chadha-Boreham [Suisse] ; Parisa Danaietash [Suisse] ; Jasper Dingemanse [Suisse] ; Samy Hadjadj [France] ; Henry Krum [Australie] ; Gerjan Navis [Pays-Bas] ; Eric Neuhart [Suisse] ; Aneliya I. Parvanova [Italie] ; Piero Ruggenenti [Italie] ; Arend Jan Woittiez [Pays-Bas] ; Reuven Zimlichman [Israël] ; Giuseppe Remuzzi [Italie] ; Dick De Zeeuw [Pays-Bas] | Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy |
| 007A67 (2010) |
LEI CHEN [Australie] ; Dianna J. Magliano [Australie] ; Beverley Balkau [Australie] ; Stephen Colagiuri [France] ; Paul Z. Zimmet [Australie] ; Andrew M. Tonkin [Australie] ; Paul Mitchell [Australie] ; Patrick J. Phillips [Australie] ; Jonathan E. Shaw [Australie] | AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures |
| 007E32 (2009) |
M. Marre [Australie] ; J. Shaw [Australie] ; M. Br Ndle [Australie] ; W. M. W. Bebakar [Australie] ; N. A. Kamaruddin [Australie] ; J. Strand [Australie] ; M. Zdravkovic [Australie] ; T. D. Le Thi [Australie] ; S. Colagiuri [Australie] | Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU) |
| 008235 (2009) |
Bastiaan E. De Galan [Australie, Pays-Bas] ; Vlado Perkovic [Australie] ; Toshiharu Ninomiya [Australie] ; Avinesh Pillai [Australie] ; Anushka Patel [Australie] ; Alan Cass [Australie] ; Bruce Neal [Australie] ; Neil Poulter [Royaume-Uni] ; Stephen Harrap [Australie] ; Carl-Erik Mogensen [Danemark] ; Mark Cooper [Australie] ; Michel Marre [France] ; Bryan Williams [Royaume-Uni] ; Pavel Hamet [Canada] ; Giuseppe Mancia [Italie] ; Mark Woodward [Australie] ; Paul Glasziou [Royaume-Uni] ; Diederick E. Grobbee [Pays-Bas] ; Stephen Macmahon [Australie] ; John Chalmers [Australie] | Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes |
